Kilambi News
Sunday, November 22, 2026

Archive

Every story, newest first.

Saturday, October 31, 2026

Technology

United chief doubts Boom 2029 timeline as turbines take focus

United Airlines chief executive Scott Kirby said Boom Supersonic's Overture airliner will not be ready in 2029, its official timeline, as Boom pushes a 42 megawatt natural gas turbine for AI data centres that has already lost its 1.25 billion dollar launch customer, Crusoe.

Technology

Trojanised Claude Code extension on Cursor planted SSH backdoor

A malicious version of Anthropic's official Claude Code extension, version 2.1.313, was distributed through the Cursor marketplace for about 11 hours on October 29, affecting at most 5,000 users and attempting to install a persistent SSH backdoor, Cursor said in its own security notice.

Technology

Technology also notable: Equinix bookings, OpenAI silicon, FCC spectrum

Equinix's third quarter included record annualised gross bookings of 533 million dollars, up 35 percent, Lightmatter's lead ASIC engineer has joined OpenAI as silicon lead, and the FCC is seeking comment on freeing 500 megahertz of spectrum for direct to device services.

Life Sciences

Parse and Nomic build 100 million cell immune dataset

Parse Biosciences and Nomic Bio announced Cascade, a licensable dataset combining 100 million single cell RNA profiles with more than 11,000 proteomic secretome profiles across over 150,000 perturbation conditions, with GSK, Pfizer and Sanofi among the founding partners.

Life Sciences

Opentrons raises $40 million to scale AI lab robotics

Opentrons Labworks announced a 40 million dollar Series E led by Avego, with BroadOak Capital Partners participating, to scale its laboratory robotics, software and data infrastructure for AI driven experimentation.

Life Sciences

Moderna shares slide despite strong cancer vaccine data

Moderna shares fell by double digits during the ESMO congress even though detailed data for intismeran autogene, its personalised cancer vaccine with Merck, appeared to meet high expectations after a landmark melanoma trial win in August.

Life Sciences

Ivonescimab extends survival in biliary tract cancer trial

Akeso ivonescimab plus chemotherapy extended median overall survival to 14.9 months against 12.1 months for durvalumab plus chemotherapy in the Phase 3 HARMONi-GI1 trial in first line biliary tract cancer, a hazard ratio of 0.75, presented at ESMO.

Life Sciences

First Keytruda biosimilar enters FDA review without Phase 3

The FDA has accepted for review Formycon and Zydus FYB206, the first publicly announced Keytruda biosimilar application, with a decision possible in the third quarter of 2027 and no comparative Phase 3 efficacy trial required.

Life Sciences

EMA safety committee opens Deanxit and immunoglobulin reviews

The European Medicines Agency safety committee PRAC said on October 30 it has started reviews of the depression and anxiety medicine Deanxit and of allergic reactions linked to specific batches of human normal immunoglobulin medicines.

Life Sciences

Also notable in life sciences on October 31

Seven smaller life sciences developments on October 31 include a 46 percent response rate for Xencor kidney cancer antibody at ESMO, Enanta chief executive Jay Luly retirement after 23 years, and an uncorroborated report on Sanofi European pricing strategy.